Compare · GH vs HUM
GH vs HUM
Side-by-side comparison of Guardant Health Inc. (GH) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GH and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $46.33B, about 2.4x GH ($19.64B).
- GH has been more active in the news (25 items in the past 4 weeks vs 18 for HUM).
- Both have 25 recent analyst ratings on file.
- Company
- Guardant Health Inc.
- Humana Inc.
- Price
- -
- -
- Market cap
- $19.64B
- $46.33B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 25
- 18
- Recent ratings
- 25
- 25
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest GH
- Director Medina Manuel Hidalgo converted options into 232 shares, increasing direct ownership by 4% to 5,484 units (SEC Form 4)
- Director Alex M Azar II sold $10,320 worth of shares (69 units at $149.56), decreasing direct ownership by 7% to 962 units (SEC Form 4)
- Director Musa Tariq converted options into 250 shares and sold $17,349 worth of shares (116 units at $149.56), increasing direct ownership by 1% to 11,717 units (SEC Form 4)
- Guardant Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Director Azar Alex M Ii converted options into 138 shares, increasing direct ownership by 15% to 1,031 units (SEC Form 4)
- Director Sayer Kevin R was granted 3,149 restricted stock units (SEC Form 4)
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New insider Sayer Kevin R claimed no ownership of stock in the company (SEC Form 3)
- Chief Accounting Officer Parks Robert was granted 18,893 restricted stock units (SEC Form 4)
- New insider Parks Robert claimed no ownership of stock in the company (SEC Form 3)
Latest HUM
- Florida Seniors and Primary Care Providers Agree that Prevention, Affordable Care and Comprehensive Coverage are Keys to Healthy Aging
- Humana Foundation Marks 45 Years With Nearly $14 Million in Grants to Expand Healthy Food Access and Help Seniors Feel More Connected
- Humana to Launch National Gold Card Program to Reduce Prior Authorization Requirements
- Humana Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Humana Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
- Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities
- Humana upgraded by RBC Capital Mkts with a new price target
- Director Frederick Wayne A.I. sold $193,853 worth of Humana Common (440 units at $440.57), closing all direct ownership in the company (SEC Form 4)
- President, Enterprise Growth Dintenfass David gifted 230 units of Humana Common, decreasing direct ownership by 0.91% to 25,177 units (SEC Form 4)
- Chief Legal Officer Ventura Joseph C sold $2,384,013 worth of Humana Common (5,495 units at $433.85) and gifted 437 units of Humana Common, decreasing direct ownership by 22% to 21,473 units (SEC Form 4)